Literature DB >> 3492271

Effect of chemical deglycosylation of ricin A chain on the in vivo fate and cytotoxic activity of an immunotoxin composed of ricin A chain and anti-Thy 1.1 antibody.

D C Blakey, G J Watson, P P Knowles, P E Thorpe.   

Abstract

The carbohydrate present on ricin A chain causes ricin A chain immunotoxins to be cleared rapidly in animals by the reticuloendothelial system. In an effort to overcome this problem we destroyed the carbohydrate on ricin A chain by treating it with a mixture of sodium metaperiodate and sodium cyanoborohydride and then linked the "deglycosylated" A chain to monoclonal anti-Thy 1.1 antibody. The deglycosylation procedure did not affect the ability of the A chain component of the immunotoxin to inhibit protein synthesis in a cell-free system or the capacity of the immunotoxin to inhibit protein synthesis in Thy-1.1 positive lymphoma cells in vitro. Immunotoxins prepared with deglycosylated A chain were cleared from the bloodstream of mice more slowly than native ricin A chain immunotoxins. The difference in the blood clearance rates of the two immunotoxins could be accounted for by a decreased entrapment of the deglycosylated ricin A chain immunotoxin by the liver. Both immunotoxins broke down in vivo with the appearance of free antibody in the bloodstream. The site of cleavage of the immunotoxin was possibly the liver because immunotoxins taken up by it rapidly became unreactive with antiricin but retained reactivity with anti-mouse immunoglobulin G suggesting that dissociation of the A chain from the antibody had occurred. The immunotoxins taken up by the liver were metabolized further and the acid insoluble radioactive metabolites gradually accumulated in the stomach, thyroid, and salivary gland. The deglycosylated ricin A chain immunotoxin should be a more effective antitumor agent in vivo because it is cleared from the blood more slowly and so has greater opportunity to localize within the tumor target.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3492271

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  22 in total

Review 1.  Monoclonal antibodies. Future potential in cancer chemotherapy.

Authors:  C Kosmas; H Kalofonos; A A Epenetos
Journal:  Drugs       Date:  1989-11       Impact factor: 9.546

Review 2.  Immunotoxins for targeted cancer therapy.

Authors:  Robert J Kreitman
Journal:  AAPS J       Date:  2006-08-18       Impact factor: 4.009

Review 3.  Immunotoxins for the treatment of B-cell lymphomas.

Authors:  M A Ghetie; V Ghetie; E S Vitetta
Journal:  Mol Med       Date:  1997-07       Impact factor: 6.354

Review 4.  Antibody mediated targeting of radioisotopes, drugs and toxins in diagnosis and treatment.

Authors:  C H Ford; V J Richardson; V S Reddy
Journal:  Indian J Pediatr       Date:  1990 Jan-Feb       Impact factor: 1.967

Review 5.  Immunotoxins against solid tumors.

Authors:  R Pirker
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553

6.  Biodistribution and plasma survival in mice of anti-melanoma monoclonal antibody cross-linked to OKT3.

Authors:  M A Winkler; J O Price; P D Foglesong; W H West
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

7.  Preclinical investigation of the antitumour effects of anti-CD19-idarubicin immunoconjugates.

Authors:  A J Rowland; G A Pietersz; I F McKenzie
Journal:  Cancer Immunol Immunother       Date:  1993-08       Impact factor: 6.968

8.  Endocytosis of ricin by rat liver cells in vivo and in vitro is mainly mediated by mannose receptors on sinusoidal endothelial cells.

Authors:  S Magnússon; T Berg
Journal:  Biochem J       Date:  1993-05-01       Impact factor: 3.857

9.  Pharmacokinetics, tissue distribution, and in vivo antitumor effects of the antimelanoma immunotoxin ZME-gelonin.

Authors:  K Mujoo; L Cheung; J L Murray; M G Rosenblum
Journal:  Cancer Immunol Immunother       Date:  1995-05       Impact factor: 6.968

10.  Tumour targeting with antibody-coupled liposomes: failure to achieve accumulation in xenografts and spontaneous liver metastases.

Authors:  S Matzku; H Krempel; H P Weckenmann; V Schirrmacher; H Sinn; H Stricker
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.